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raynaud’s phenomenon  is a vasospastic disorder of the digital vessels triggered by exposure to cold 
or stress. 
It is most commonly observed in the hands, but also frequently affects the toes. We present three 
cases of patients with severe raynaud’s phenomenon  in the toes, secondary to scleroderma. the 
diagnosis of raynaud’s syndrome and scleroderma was established according 
to the 2010 american College of rheumatology and european League against rheumatism criteria. 
patients were treated with 10 units of botulinum toxin injected into each foot. two millilitres was 
injected into the 
base of each toe in both the left and right feet. six weeks postinjection into the toes, patients 
reported an improvement of cold intolerance, colour change and frequency and severity of 
raynaud’s attacks. the effects were reported to last up to 5 months. to our knowledge, these are the 





Raynaud’s   phenomenon   (RP)   is   a   vasospastic disorder  of the digital vessels triggered by 
exposure to cold or stress. It is most commonly  observed  in the hands but is also frequently  occurs 
in toes.1  This transient  digital  ischaemia  is classically character- ised by three phases: (1) 
ischaemia, (2) cyanosis and (3)  reperfusion, with  patient  experiencing colour changes from white 
to blue to red.2  The prevalence of RP in the general population is between 3% and 
5% and it is more  common  in women  with a ratio of 4:1 (F:M).1 Patients often report severe pain, 
paraesthesia  and swelling of the toes and feet. 
Primary RP (Raynaud’s disease) is idiopathic. Secondary RP (Raynaud’s syndrome) has several causes 
and often occurs in the context of underlying autoimmune or  connective  tissue diseases. Sclero- 
derma  is the most common  cause; 90% of patients have RP. Other  causes include Sjorgen’s 
disease, rheumatoid arthritis, systemic lupus erythematosus (SLE),  the   contraceptive  pill/oral   
contraceptives and  β-blockers.  These  patients  present  later,  with more  severe  disease  and  
associated  complications such as ulceration, gangrene and possible ampu- tation.1–3  It is an 
important therapeutic challenge. 
The  medical  treatment options  for  RP depend  on the underlying cause and severity. Patients with 
secondary  RP are much more clinically challenging to treat  as digital vasospasm  can be aggravated  
by other   disease  manifestations.  Botulinum   toxin   A 
  
(Btx-A) is a neurotoxin produced by Clostridium botulinum.4 It has shown  promise  as a therapeutic 
option  for  patients  with  severe  RP in  the  fingers that  is refractory  to other  treatments.2 3  
However, overall evidence conflicting and further  randomised controlled trials  (RCTs)  are  needed  
if Btx-A is to become  a viable  treatment option.5  Furthermore, there  are currently  no studies in 
the literature that report  the use of Btx-A for the treatment of RP in the toes. 
 
Case Presentation 
Three  patients  with RP secondary  to scleroderma, according to the criteria for systemic sclerosis of 
the American College of Rheumatology and European League Against Rheumatism criteria,  
presented to clinic. They all had moderate  to severe scleroderma with  severe  RP  that   was  
refractory   to  previous medical treatment. No other concurrent treatments were  changed  or  
interrupted. See table  1 for  full patient  drug  history.  All patients  were women  and aged between 
42 and 64 years. In addition  to hand symptoms,  they  also reported moderate  to  severe pain,  




The  patients  were  treated  with  10  units  of Btx-A (Botox;   Allergan,  Marlow,   UK)  reconstituted  
in 2 mL of saline,  per  foot.  Two  units  were  injected into  each  toe,  around  the  neurovascular 
bundles, of both  the  left and  right  feet. All injections  were performed by the  senior  author  
PEMB.  Thermo- graphic images of the feet were taken pre-Btx-A injection   (figure   1A)   and   6   
weeks   post-Btx-A injection  (figure 1B). Thermographic imaging was carried out after a period  of 20 
min acclimatisation in a temperature controlled room  at (23±0.5°C). Patients  wore  their  own 
clothes but were asked to remove  shoes  and  socks.  The  patients  were  also asked  to  complete  a 
daily Raynaud’s  attack  diary for 6 weeks. After 6 weeks, they returned to clinic for a follow-up  
assessment. 
 
Outcome and Follow-up 
Six weeks postinjection, all three of the patients reported a large improvement in pain, colour 
changes and   cold  intolerance.  All  three   had   an  increase in  temperature  6 weeks  
postinjection.  Two  of  the patients  also reported a reduction in the  frequency and  severity  of  
Raynaud’s  attacks  with  a  quicker  
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novel  treatment (new drug/intervention; established drug/procedure in new situation) 
  
Table 1    Patient drug history 
patient 
number         raynaud’s medications                                     other 
1                    Losartan                                                             Nil 
2                    Losartan                                                             Thyroxine 
Nifedipine 
3                    Nil currently                                                       Fluoxetine 
Had previously tried losartan, nifedipine and iloprost infusions 
recovery  when  attacks  occurred.   The  other  patient  reported  a reduction in swelling of the feet. 
She previously had to wear two differently  sized shoes due to foot  swelling. Six weeks postinjec- 
tion, she reported the swelling had reduced  shoe size in one foot reduced by half a size. 
Thermographic imaging showed an increase in the temperature of the toes 6 weeks post injection  
(figure 1B) compared with pre-Btx-A treatment (figure 1A). 
A retrospective telephone questionnaire found that the duration of effects were variable and ranged 
between 7 weeks and 5 months. All of the patients would have further  Btx-A injection into the toes 
and would also recommend it to other patients. 
 
Discussion 
The treatment options  for severe RP that is refractory  to medical treatment  are  very  limited.  
Where  medical  management  fails, surgical interventions are usually the  next  step.  Current 
surgical options,  such  as digital  sympathectomy,  have  the  potential for severe complications  
with limited  success.6 7  A systematic review found  that  of those  patients  having digital 
sympathectomy, 40% of patients have postoperative complications, 20% have continued ulceration  
and 15% go on to have amputations.8 The outcomes of digital sympathectomy of the toes is poorly  
reported in the liter- ature.  There  is currently  only one case report  that shows varying degrees  of  
success in  symptom  improvement and  ulcer  healing in patients  with scleroderma.9 10  Botulinum  
toxin  offers an addi- tional, non-operative, treatment option for these patients.  It is also unique in 
that it provides a localised treatment option,  limiting the systemic side effects. All of the studies in 
the literature report its use in patients  with finger symptoms.  However, the majority of these 
patients also experience  the same symptoms in the toes. There are currently  no local treatments 
for toe symptoms. 
We found that the temperature of the toes improved  after Btx-A injection.  It is known  that  Btx-A 
acts by inhibiting  the release of acetylcholine  release at the neuromuscular junction  by binding to 
the SNAP-25 protein.2 However, the known mechanism    
of action is unable to account for the results seen when it is used in the treat- ment  of RP. Although  
this mechanism  of action  is currently  not fully understood, it is thought that  Btx-A causes 




figure 1    Patient 1 (A) Pre-Btx-A injection,  (B) 6 weeks post-Btx-A 




the inhibition  of sympathetic  neuronal transmission. Blocking the release  of norepinephrine and  
other  vasoconstrictive  substances causes  vasodilation   at  the  neuromuscular  junction   of  
smooth muscle. This results in an increased  blood  supply to the digits.11 
This is supported by a recent  study that  found  an increase in the viability of skin flaps after Btx-A 
injection.12 
From this case report, we found that Btx-A improved  symptoms in patients  with RP affecting the 
toes that is refractory  to medical management. The Btx-A was well tolerated and results were prom- 
ising. Further, larger controlled trial are needed  to further  investi- gate the role of Btx-A in 




► Raynaud’s phenomenon (RP) is a vasospastic disorder of the digital vessels triggered by exposure 
to cold or stress. 
► It is most commonly observed in the hands, but also frequently affects the toes. 
► Botulinum  toxin A (Btx-A) is a potential treatment option in those patients with severe RP in the 
fingers that is refractory to other treatment, however further RCTs are needed if Btx-A is to become 
a viable treatment option. 
► On the basis of our case report,  Btx-A has been shown to improve symptoms in patients with RP 
affecting the toes that is refractory to medical management. 
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